Brenus Pharma attended the SITC EU Immuno-Oncology Drug Development Summit in Lausanne.
Published
Signal category
Presence & Recognition
Quote
“Back from the SITC EU Immuno-Oncology Drug Development Summit in Lausanne.”
— Iseulys Richert|Brenus Pharma team
Company
Brenus Pharma
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
- Industry
- Biotechnology
- Location
- Lyon, FR
- Company size
- 31 employees
Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply. Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development. We are currently envisaging clinical collaborations. Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.
Founded 2019